Generics Global Group of Eight (G8) Industry Guide_2017

mli0156 MarketLine 28 February, 2017 160 pages

Select License

Report Description
Table of Contents
Related Reports

Summary

The G8 Generics industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the G8 generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends and leading companies.

- The G8 countries contributed $189.4 billion in 2016 to the global generics industry, with a compound annual growth rate (CAGR) of 10.9% between 2012 and 2016. The G8 countries are expected to reach a value of $384.0 billion in 2021, with a CAGR of 15.2% over the 2016-21 period.

- Among the G8 nations, the US is the leading country in the generics industry, with market revenues of $99.7 billion in 2016. This was followed by Japan and Germany, with a value of $56.6 and $8.5 billion, respectively.

- Japan is expected to lead the generics industry in the G8 nations with a value of $199.9 billion in 2016, followed by the US and the UK with expected values of $141.2 and $12.1 billion, respectively.

Scope

- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the G8 generics market

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the G8 generics market

- Leading company profiles reveal details of key generics market players’ G8 operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the G8 generics market with five year forecasts by both value and volume

- Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country

Reasons to buy

- What was the size of the G8 generics market by value in 2016?

- What will be the size of the G8 generics market in 2021?

- What factors are affecting the strength of competition in the G8 generics market?

- How has the market performed over the last five years?

- Who are the top competitors in the G8 generics market?

Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
Group of Eight (G) Generics
Industry Outlook
Generics in Canada
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in France
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Germany
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Italy
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Japan
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Russia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The United Kingdom
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The United States
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
About MarketLine

List of Tables

1Table 1: G8 generics industry, revenue($bn), 2012-21
2Table 2: G8 generics industry, revenue by country ($bn), 2012-16
3Table 3: G8 generics industry forecast, revenue by country ($bn), 2016-21
4Table 4: Canada generics market value: $ billion, 2012–16
5Table 5: Canada generics market volume: % of total pharma volume, 2012–16
6Table 6: Canada generics market geography segmentation: $ billion,2016
7Table 7: Canada generics market value forecast: $ billion, 2016–21
8Table 8: Canada generics market volume forecast: % of total pharma volume, 2016–21
9Table 9: Canada size of population (million), 2012–16
10Table 10: Canada gdp (constant 2005 prices, $ billion), 2012–16
11Table 11: Canada gdp (current prices, $ billion), 2012–16
12Table 12: Canada inflation, 2012–16
13Table 13: Canada consumer price index (absolute), 2012–16
14Table 14: Canada exchange rate, 2012–16
15Table 15: France generics market value: $ billion, 2012–16
16Table 16: France generics market volume: % of total pharma volume, 2012–16
17Table 17: France generics market geography segmentation: $ billion,2016
18Table 18: France generics market value forecast: $ billion, 2016–21
19Table 19: France generics market volume forecast: % of total pharma volume, 2016–21
20Table 20: France size of population (million), 2012–16
21Table 21: France gdp (constant 2005 prices, $ billion), 2012–16
22Table 22: France gdp (current prices, $ billion), 2012–16
23Table 23: France inflation, 2012–16
24Table 24: France consumer price index (absolute), 2012–16
25Table 25: France exchange rate, 2012–16
26Table 26: Germany generics market value: $ billion, 2012–16
27Table 27: Germany generics market volume: % of total pharma volume, 2012–16
28Table 28: Germany generics market geography segmentation: $ billion,2016
29Table 29: Germany generics market value forecast: $ billion, 2016–21
30Table 30: Germany generics market volume forecast: % of total pharma volume, 2016–21
31Table 31: Germany size of population (million), 2012–16
32Table 32: Germany gdp (constant 2005 prices, $ billion), 2012–16
33Table 33: Germany gdp (current prices, $ billion), 2012–16
34Table 34: Germany inflation, 2012–16
35Table 35: Germany consumer price index (absolute), 2012–16
36Table 36: Germany exchange rate, 2012–16
37Table 37: Italy generics market value: $ billion, 2012–16
38Table 38: Italy generics market volume: % of total pharma volume, 2012–16
39Table 39: Italy generics market geography segmentation: $ billion,2016
40Table 40: Italy generics market value forecast: $ billion, 2016–21
41Table 41: Italy generics market volume forecast: % of total pharma volume, 2016–21
42Table 42: Italy size of population (million), 2012–16
43Table 43: Italy gdp (constant 2005 prices, $ billion), 2012–16
44Table 44: Italy gdp (current prices, $ billion), 2012–16
45Table 45: Italy inflation, 2012–16
46Table 46: Italy consumer price index (absolute), 2012–16
47Table 47: Italy exchange rate, 2012–16
48Table 48: Japan generics market value: $ billion, 2012–16
49Table 49: Japan generics market volume: % of total pharma volume, 2012–16
50Table 50: Japan generics market geography segmentation: $ billion,2016
51Table 51: Japan generics market value forecast: $ billion, 2016–21
52Table 52: Japan generics market volume forecast: % of total pharma volume, 2016–21
53Table 53: Japan size of population (million), 2012–16
54Table 54: Japan gdp (constant 2005 prices, $ billion), 2012–16
55Table 55: Japan gdp (current prices, $ billion), 2012–16
56Table 56: Japan inflation, 2012–16
57Table 57: Japan consumer price index (absolute), 2012–16
58Table 58: Japan exchange rate, 2012–16
59Table 59: Russia generics market value: $ billion, 2012–16
60Table 60: Russia generics market volume: % of total pharma volume, 2012–16
61Table 61: Russia generics market geography segmentation: $ billion,2016
62Table 62: Russia generics market value forecast: $ billion, 2016–21
63Table 63: Russia generics market volume forecast: % of total pharma volume, 2016–21
64Table 64: Russia size of population (million), 2012–16
65Table 65: Russia gdp (constant 2005 prices, $ billion), 2012–16
66Table 66: Russia gdp (current prices, $ billion), 2012–16
67Table 67: Russia inflation, 2012–16
68Table 68: Russia consumer price index (absolute), 2012–16
69Table 69: Russia exchange rate, 2012–16
70Table 70: United Kingdom generics market value: $ billion, 2012–16
71Table 71: United Kingdom generics market volume: % of total pharma volume, 2012–16
72Table 72: United Kingdom generics market geography segmentation: $ billion,2016
73Table 73: United Kingdom generics market value forecast: $ billion, 2016–21
74Table 74: United Kingdom generics market volume forecast: % of total pharma volume, 2016–21
75Table 75: United Kingdom size of population (million), 2012–16
76Table 76: United Kingdom gdp (constant 2005 prices, $ billion), 2012–16
77Table 77: United Kingdom gdp (current prices, $ billion), 2012–16
78Table 78: United Kingdom inflation, 2012–16
79Table 79: United Kingdom consumer price index (absolute), 2012–16
80Table 80: United Kingdom exchange rate, 2012–16
81Table 81: United States generics market value: $ billion, 2012–16
82Table 82: United States generics market volume: % of total pharma volume, 2012–16
83Table 83: United States generics market geography segmentation: $ billion,2016
84Table 84: United States generics market value forecast: $ billion, 2016–21
85Table 85: United States generics market volume forecast: % of total pharma volume, 2016–21
86Table 86: United States size of population (million), 2012–16
87Table 87: United States gdp (constant 2005 prices, $ billion), 2012–16
88Table 88: United States gdp (current prices, $ billion), 2012–16
89Table 89: United States inflation, 2012–16
90Table 90: United States consumer price index (absolute), 2012–16
91Table 91: United States exchange rate, 2012–15
92Table 92: Apotex, Inc.: key facts
93Table 93: Mylan Inc.: key facts
94Table 94: Mylan Inc.: key financials ($)
95Table 95: Mylan Inc.: key financial ratios
96Table 96: Sandoz International GmbH: key facts
97Table 97: Teva Pharmaceutical Industries Limited: key facts
98Table 98: Teva Pharmaceutical Industries Limited: key financials ($)
99Table 99: Teva Pharmaceutical Industries Limited: key financial ratios
100Table 100: Les Laboratoires Servier: key facts
101Table 101: STADA Arzneimittel AG: key facts
102Table 102: STADA Arzneimittel AG: key financials ($)
103Table 103: STADA Arzneimittel AG: key financials (€)
104Table 104: STADA Arzneimittel AG: key financial ratios
105Table 105: Sanofi SA: key facts
106Table 106: Sanofi SA: key financials ($)
107Table 107: Sanofi SA: key financials (€)
108Table 108: Sanofi SA: key financial ratios
109Table 109: Daiichi Sankyo Co., Ltd.: key facts
110Table 110: Daiichi Sankyo Co., Ltd.: key financials ($)
111Table 111: Daiichi Sankyo Co., Ltd.: key financials (¥)
112Table 112: Daiichi Sankyo Co., Ltd.: key financial ratios
113Table 113: Sawai Pharmaceutical Co., Ltd.: key facts
114Table 114: Sawai Pharmaceutical Co., Ltd.: key financials ($)
115Table 115: Sawai Pharmaceutical Co., Ltd.: key financials (¥)
116Table 116: Sawai Pharmaceutical Co., Ltd.: key financial ratios
117Table 117: Abbott Laboratories: key facts
118Table 118: Abbott Laboratories: key financials ($)
119Table 119: Abbott Laboratories: key financial ratios
120Table 120: Krka, d. d., Novo mesto: key facts
121Table 121: Krka, d. d., Novo mesto: key financials ($)
122Table 122: Krka, d. d., Novo mesto: key financials (€)
123Table 123: Krka, d. d., Novo mesto: key financial ratios

List of Figures

1Figure 1: G8 generics industry, revenue($bn), 2012-21
2Figure 2: G8 Generics industry, revenue by country (%),2016
3Figure 3: G8 generics industry, revenue by country ($bn), 2012-16
4Figure 4: G8 generics industry forecast, revenue by country ($bn), 2016-21
5Figure 5: Canada generics market value: $ billion, 2012–16
6Figure 6: Canada generics market volume: % of total pharma volume, 2012–16
7Figure 7: Canada generics market geography segmentation: % share, by value,2016
8Figure 8: Canada generics market value forecast: $ billion, 2016–21
9Figure 9: Canada generics market volume forecast: % of total pharma volume, 2016–21
10Figure 10: Forces driving competition in the generics market in Canada,2016
11Figure 11: Drivers of buyer power in the generics market in Canada,2016
12Figure 12: Drivers of supplier power in the generics market in Canada,2016
13Figure 13: Factors influencing the likelihood of new entrants in the generics market in Canada,2016
14Figure 14: Factors influencing the threat of substitutes in the generics market in Canada,2016
15Figure 15: Drivers of degree of rivalry in the generics market in Canada,2016
16Figure 16: France generics market value: $ billion, 2012–16
17Figure 17: France generics market volume: % of total pharma volume, 2012–16
18Figure 18: France generics market geography segmentation: % share, by value,2016
19Figure 19: France generics market value forecast: $ billion, 2016–21
20Figure 20: France generics market volume forecast: % of total pharma volume, 2016–21
21Figure 21: Forces driving competition in the generics market in France,2016
22Figure 22: Drivers of buyer power in the generics market in France,2016
23Figure 23: Drivers of supplier power in the generics market in France,2016
24Figure 24: Factors influencing the likelihood of new entrants in the generics market in France,2016
25Figure 25: Factors influencing the threat of substitutes in the generics market in France,2016
26Figure 26: Drivers of degree of rivalry in the generics market in France,2016
27Figure 27: Germany generics market value: $ billion, 2012–16
28Figure 28: Germany generics market volume: % of total pharma volume, 2012–16
29Figure 29: Germany generics market geography segmentation: % share, by value,2016
30Figure 30: Germany generics market value forecast: $ billion, 2016–21
31Figure 31: Germany generics market volume forecast: % of total pharma volume, 2016–21
32Figure 32: Forces driving competition in the generics market in Germany,2016
33Figure 33: Drivers of buyer power in the generics market in Germany,2016
34Figure 34: Drivers of supplier power in the generics market in Germany,2016
35Figure 35: Factors influencing the likelihood of new entrants in the generics market in Germany,2016
36Figure 36: Factors influencing the threat of substitutes in the generics market in Germany,2016
37Figure 37: Drivers of degree of rivalry in the generics market in Germany,2016
38Figure 38: Italy generics market value: $ billion, 2012–16
39Figure 39: Italy generics market volume: % of total pharma volume, 2012–16
40Figure 40: Italy generics market geography segmentation: % share, by value,2016
41Figure 41: Italy generics market value forecast: $ billion, 2016–21
42Figure 42: Italy generics market volume forecast: % of total pharma volume, 2016–21
43Figure 43: Forces driving competition in the generics market in Italy,2016
44Figure 44: Drivers of buyer power in the generics market in Italy,2016
45Figure 45: Drivers of supplier power in the generics market in Italy,2016
46Figure 46: Factors influencing the likelihood of new entrants in the generics market in Italy,2016
47Figure 47: Factors influencing the threat of substitutes in the generics market in Italy,2016
48Figure 48: Drivers of degree of rivalry in the generics market in Italy,2016
49Figure 49: Japan generics market value: $ billion, 2012–16
50Figure 50: Japan generics market volume: % of total pharma volume, 2012–16
51Figure 51: Japan generics market geography segmentation: % share, by value,2016
52Figure 52: Japan generics market value forecast: $ billion, 2016–21
53Figure 53: Japan generics market volume forecast: % of total pharma volume, 2016–21
54Figure 54: Forces driving competition in the generics market in Japan,2016
55Figure 55: Drivers of buyer power in the generics market in Japan,2016
56Figure 56: Drivers of supplier power in the generics market in Japan,2016
57Figure 57: Factors influencing the likelihood of new entrants in the generics market in Japan,2016
58Figure 58: Factors influencing the threat of substitutes in the generics market in Japan,2016
59Figure 59: Drivers of degree of rivalry in the generics market in Japan,2016
60Figure 60: Russia generics market value: $ billion, 2012–16
61Figure 61: Russia generics market volume: % of total pharma volume, 2012–16
62Figure 62: Russia generics market geography segmentation: % share, by value,2016
63Figure 63: Russia generics market value forecast: $ billion, 2016–21
64Figure 64: Russia generics market volume forecast: % of total pharma volume, 2016–21
65Figure 65: Forces driving competition in the generics market in Russia,2016
66Figure 66: Drivers of buyer power in the generics market in Russia,2016
67Figure 67: Drivers of supplier power in the generics market in Russia,2016
68Figure 68: Factors influencing the likelihood of new entrants in the generics market in Russia,2016
69Figure 69: Factors influencing the threat of substitutes in the generics market in Russia,2016
70Figure 70: Drivers of degree of rivalry in the generics market in Russia,2016
71Figure 71: United Kingdom generics market value: $ billion, 2012–16
72Figure 72: United Kingdom generics market volume: % of total pharma volume, 2012–16
73Figure 73: United Kingdom generics market geography segmentation: % share, by value,2016
74Figure 74: United Kingdom generics market value forecast: $ billion, 2016–21
75Figure 75: United Kingdom generics market volume forecast: % of total pharma volume, 2016–21
76Figure 76: Forces driving competition in the generics market in the United Kingdom,2016
77Figure 77: Drivers of buyer power in the generics market in the United Kingdom,2016
78Figure 78: Drivers of supplier power in the generics market in the United Kingdom,2016
79Figure 79: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom,2016
80Figure 80: Factors influencing the threat of substitutes in the generics market in the United Kingdom,2016
81Figure 81: Drivers of degree of rivalry in the generics market in the United Kingdom,2016
82Figure 82: United States generics market value: $ billion, 2012–16
83Figure 83: United States generics market volume: % of total pharma volume, 2012–16
84Figure 84: United States generics market geography segmentation: % share, by value,2016
85Figure 85: United States generics market value forecast: $ billion, 2016–21
86Figure 86: United States generics market volume forecast: % of total pharma volume, 2016–21
87Figure 87: Forces driving competition in the generics market in the United States,2016
88Figure 88: Drivers of buyer power in the generics market in the United States,2016
89Figure 89: Drivers of supplier power in the generics market in the United States,2016
90Figure 90: Factors influencing the likelihood of new entrants in the generics market in the United States,2016
91Figure 91: Factors influencing the threat of substitutes in the generics market in the United States,2016
92Figure 92: Drivers of degree of rivalry in the generics market in the United States,2016
93Figure 93: Mylan Inc.: revenues & profitability
94Figure 94: Mylan Inc.: assets & liabilities
95Figure 95: Teva Pharmaceutical Industries Limited: revenues & profitability
96Figure 96: Teva Pharmaceutical Industries Limited: assets & liabilities
97Figure 97: STADA Arzneimittel AG: revenues & profitability
98Figure 98: STADA Arzneimittel AG: assets & liabilities
99Figure 99: Sanofi SA: revenues & profitability
100Figure 100: Sanofi SA: assets & liabilities
101Figure 101: Daiichi Sankyo Co., Ltd.: revenues & profitability
102Figure 102: Daiichi Sankyo Co., Ltd.: assets & liabilities
103Figure 103: Sawai Pharmaceutical Co., Ltd.: revenues & profitability
104Figure 104: Sawai Pharmaceutical Co., Ltd.: assets & liabilities
105Figure 105: Abbott Laboratories: revenues & profitability
106Figure 106: Abbott Laboratories: assets & liabilities
107Figure 107: Krka, d. d., Novo mesto: revenues & profitability
108Figure 108: Krka, d. d., Novo mesto: assets & liabilities